AR061540A1 - ORAL PHARMACEUTICAL COMPOSITION IMPROVED OF AN ACTIVE WATER SOLUBLE AGENT IN WATER - Google Patents
ORAL PHARMACEUTICAL COMPOSITION IMPROVED OF AN ACTIVE WATER SOLUBLE AGENT IN WATERInfo
- Publication number
- AR061540A1 AR061540A1 ARP070102708A AR061540A1 AR 061540 A1 AR061540 A1 AR 061540A1 AR P070102708 A ARP070102708 A AR P070102708A AR 061540 A1 AR061540 A1 AR 061540A1
- Authority
- AR
- Argentina
- Prior art keywords
- weight
- water
- oral pharmaceutical
- pharmaceutical composition
- soluble agent
- Prior art date
Links
- 239000008203 oral pharmaceutical composition Substances 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 6
- 102000003729 Neprilysin Human genes 0.000 abstract 2
- 108090000028 Neprilysin Proteins 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- XMQODGUTLZXUGZ-RPBOFIJWSA-N 2-[(3s)-3-[[1-[(2r)-2-ethoxycarbonyl-4-phenylbutyl]cyclopentanecarbonyl]amino]-2-oxo-4,5-dihydro-3h-1-benzazepin-1-yl]acetic acid Chemical group C([C@@H](C(=O)OCC)CC1(CCCC1)C(=O)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XMQODGUTLZXUGZ-RPBOFIJWSA-N 0.000 abstract 1
- 102000048186 Endothelin-converting enzyme 1 Human genes 0.000 abstract 1
- 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 abstract 1
- 102100029112 Endothelin-converting enzyme 1 Human genes 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente se proveen composiciones farmacéuticas orales mejoradas que comprenden por lo menos un agente activo escasamente soluble en agua, preferentemente un inhibidor de ECE (enzima convertidora de endotelinas) y/o un inhibidor de NEP (endopeptidasa neutra), en una cantidad mayor del 10 % peso/peso de la composicion, más preferentemente, comprendiendo el sistema alcalino una mezcla de por lo menos dos compuestos alcalinos en la relacion 1:20 a 20:1, el agente activo es SLV-306 o sus sales, ésteres, hidratos, solvatos, isomeros o derivados, farmacéuticamente aceptables, del mismo; un sistema alcalino en una cantidad superior al 10 % peso/peso de la composicion, que preferentemente comprende una mezcla de por lo menos dos compuestos alcalinos y opcionalmente uno o más excipientes farmacéuticamente aceptables. También se proveen procesos para la preparacion de tales composiciones mejoradas, y métodos para utilizar tales composiciones.Enhanced oral pharmaceutical compositions are provided herein comprising at least one water-poorly active agent, preferably an ECE inhibitor (endothelin converting enzyme) and / or an NEP inhibitor (neutral endopeptidase), in an amount greater than 10% weight / weight of the composition, more preferably, the alkaline system comprising a mixture of at least two alkaline compounds in the ratio 1:20 to 20: 1, the active agent is SLV-306 or its salts, esters, hydrates , solvates, isomers or pharmaceutically acceptable derivatives thereof; an alkaline system in an amount greater than 10% weight / weight of the composition, which preferably comprises a mixture of at least two alkaline compounds and optionally one or more pharmaceutically acceptable excipients. Processes for the preparation of such improved compositions, and methods for using such compositions are also provided.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06115881 | 2006-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061540A1 true AR061540A1 (en) | 2008-09-03 |
Family
ID=37327215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102708 AR061540A1 (en) | 2006-06-22 | 2007-06-20 | ORAL PHARMACEUTICAL COMPOSITION IMPROVED OF AN ACTIVE WATER SOLUBLE AGENT IN WATER |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN101511344A (en) |
| AR (1) | AR061540A1 (en) |
| MX (1) | MX2008016418A (en) |
| TW (1) | TW200808356A (en) |
-
2007
- 2007-06-20 AR ARP070102708 patent/AR061540A1/en not_active Application Discontinuation
- 2007-06-21 MX MX2008016418A patent/MX2008016418A/en not_active Application Discontinuation
- 2007-06-21 CN CNA2007800234341A patent/CN101511344A/en active Pending
- 2007-06-21 TW TW96122260A patent/TW200808356A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2008016418A (en) | 2009-01-22 |
| CN101511344A (en) | 2009-08-19 |
| TW200808356A (en) | 2008-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2524320T3 (en) | Composition for the prevention or treatment of disease associated with thrombus or embolus | |
| ES2606342T3 (en) | Compositions for oral care of stannous salt and sodium tripoli phosphate and methods | |
| AR061289A1 (en) | STABILIZED PHARMACEUTICAL COMPOSITIONS THAT INCLUDE FESOTERODINE | |
| ECSP109905A (en) | 7 TYPE TOLL RECEIVER MODULATORS | |
| BR112012018384A2 (en) | solid pharmaceutical composition with enhancers and methods of preparation thereof. | |
| ES2721148T3 (en) | Pharmaceutical compositions of paclitaxel, paclitaxel analogues or paclitaxel conjugates and related methods of preparation and use | |
| NO20082744L (en) | Oral pharmaceutical dosage form comprising as active ingredients a proton pump inhibitor together with acetylsalicylic acid | |
| BR112013004455A2 (en) | compositions for gastric delivery of active agents | |
| AR062980A1 (en) | PHARMACEUTICAL COMPOSITIONS OF PIRIMIDIL-AMINO-BENZAMIDA COMPOUNDS | |
| MX385798B (en) | 17-hydroxyprogesterone ester-containing oral compositions and related methods | |
| AR072261A1 (en) | PIPERAZIN-PIRAZOLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USES OF THE SAME AS ANTICANCERIGEN AGENTS. | |
| PE20120788A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS | |
| PE20071310A1 (en) | LIQUID PHENYLEPHRINE FORMULATIONS | |
| UY27320A1 (en) | NEW PHARMACEUTICAL COMPOSITIONS | |
| NZ598839A (en) | Stabilized liquid and lyophilized adamts13 formulations | |
| CY1108700T1 (en) | DRUG ALPHA-HYDROXIC ACID RELEASE COMPOSITIONS AND METHODS OF USE | |
| CL2013002234A1 (en) | Use of a pharmaceutical composition comprising at least one prostacyclin or an analogue thereof selected from treprostinil, ilorpost, cicaprost or beraprost, and at least one phosphodiesterase 4 (pde4) inhibitor, because it serves in the prevention or treatment of cystic fibrosis . | |
| CO5630034A2 (en) | PROCEDURE AND PHARMACEUTICAL COMPOSITIONS TO TREAT ATEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED AFFECTIONS | |
| PE20130063A1 (en) | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | |
| PE20091949A1 (en) | SOLID PHARMACEUTICAL FORMULATION WITH DELAYED RELEASE | |
| AR076864A1 (en) | PROCEDURE AND COMPOSITION TO IMPROVE THE ABSORPTION OF THERAPEUTIC AGENTS | |
| CO6400138A2 (en) | ANTICHANCERIGINAL COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING IT | |
| AR066905A1 (en) | INTRANASAL ADMINISTRATION OF ASENAPINE AND CORRESPONDING PHARMACEUTICAL COMPOSITIONS | |
| BRPI0818541B8 (en) | pharmaceutical composition comprising granules including sodium picosulfate and potassium bicarbonate and its process for preparation | |
| ATE493973T1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |